Regulatory13 Aug 2026, 07:03 pm

Fischer Medical Ventures: Monitoring Agency Report for Q2 2026

AI Summary

Fischer Medical Ventures Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by Infomerics Valuation and Rating Limited, pertains to the utilization of funds raised through a preferential issue of shares and convertible warrants aggregating to ₹358.46 crore. The monitoring agency confirms there were no deviations from the objects for which the funds were raised, and no range of deviation was applicable. The report is in compliance with SEBI ICDR Regulations and the Monitoring Agency Agreement.

Key Highlights

Monitoring Agency Report for Fischer Medical Ventures Ltd filed.
Covers utilization of funds from preferential issue.
Total funds raised: ₹358.46 crore.
No deviation from fund utilization objects reported.
Report issued by Infomerics Valuation and Rating Limited.

View BSE Filing

FISCHER

Commodity Chemicals

FISCHER CHEMIC LTD.

Price Impact